30th Jul 2015 09:40
LONDON (Alliance News) - Immunotherapies development company Scancell Holdings PLC on Thursday said it has signed a deal with ImmunID to collaborate on a research project designed to predict which patients will best respond to Scancell's SCIB1 immunobody.
The study will use ImmunID's ImmunTraCkeR product before and during treatment to assess the effect of the vaccine on patients with stage three and four metastatic melanoma.
"We are delighted to be working with ImmunID. This collaboration will provide an insight into T cell diversity in patients treated with our SCIB1 vaccine and their response to the treatment over time," said Richard Goodfellow, Scancell's joint chief executive.
Shares in Scancell were up 1.2% to 27.17 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings